We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

2 hedge funds and large institutions have $9.94K invested in ELITE PHARMACEUTICAL in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 1 → 2 (+1)

99% more capital invested

Capital invested by funds: $5K → $9.94K (+$4.94K)

Holders
2
Holders Change
+1
Holders Change %
+100%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JAFL
Jay A. Fishman Ltd
Michigan
+$5.94K

Top Sellers

No sellers this quarter

ELI Hedge Fund Activity: Q1 2020 in Review

2 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q1 2020, worth a combined $9.94K — up 99% from $5K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new ELI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Jay A. Fishman Ltd, opening a new position worth an estimated $5.94K.

  • 2 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q1 2020, up from 1 in Q4 2019.
  • Funds reported $9.94K of ELITE PHARMACEUTICAL stock for Q1 2020, up 99% quarter-over-quarter.
  • 1 fund opened new ELITE PHARMACEUTICAL positions in Q1 2020 and 0 closed out, a net change of +1 holder.
  • The largest ELITE PHARMACEUTICAL buyer in Q1 2020 was Jay A. Fishman Ltd, an estimated $5.94K added.

Based on aggregated 13F filings for Q1 2020.